Company TME Pharma N.V.

Equities

ALTME

NL0015000YE1

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 11:07:30 2026-03-17 am EDT			5-day change	1st Jan Change
0.0767 ^EUR	+1.86%		+0.52%	+17.64%

Mar. 09	TME Pharma N.V. Extends Maturity of EUR 2.06 Million Loans and Announces Early Redemption of EUR 163,562.50 Bonds	CI
Mar. 09	TME Pharma Secures 12-month Loan Extension	MT

Business description: TME Pharma N.V.

TME Pharma N.V. is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. The company specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma N.V.'s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Its clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.

Number of employees: 12

Sales by Activity: TME Pharma N.V.

Fiscal Period: December	2020 (EUR)	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)
Pharmaceuticals	35K	33K	-	-	19K

See all business segments

Geographical breakdown of sales: TME Pharma N.V.

Fiscal Period: December	2020 (EUR)	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)
Germany	35K	33K	-	-	19K

See all geographic segments

Executive Committee: TME Pharma N.V.

Manager	Title	Age	Since
Diede van den Ouden CEO	Chief Executive Officer	-	2025-06-24
Jarl Ulf Birger Jungnelius CTO	Chief Tech/Sci/R&D Officer	75	2017-01-31
Aram Andrew Mangasarian CEO	Chief Executive Officer	56	2010-04-30
Ewelina Staniuk IRC	Investor Relations Contact	-	2017-12-31
Karen Ophoff HRO	Human Resources Officer	-	2000-12-31

See TME PHARMA N.V. governance

Composition of the Board of Directors: TME Pharma N.V.

Director	Title	Age	Since
Maurizio PetitBon CHM	Chairman	78	2019-06-24
Susan Coles BRD	Director/Board Member	60	2021-06-23
Lee Schalop BRD	Director/Board Member	-	2024-06-26
Diede van den Ouden BRD	Director/Board Member	-	2025-06-24

Composition of the Board of Directors

Shareholders: TME Pharma N.V.

Name	Equities	%	Valuation
Chart AG 3.982 %	3,750,964	3.982 %	305 591 €
Gestys SA 0.1699 %	160,000	0.1699 %	13 035 €

List of TME PHARMA N.V. shareholders

Company details: TME Pharma N.V.

TME Pharma NV

Max-Dohrn-Strasse 8-10

10589, Berlin

http://www.tmepharma.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
TME PHARMA N.V.	+1.86%	+0.52%	+5.94%	-93.03%	8.13M
LONZA GROUP AG	+0.26%	-2.44%	-13.50%	-9.22%	42.95B
BEONE MEDICINES AG	-0.97%	-5.51%	+8.86%	+29.21%	32.12B
CELLTRION, INC.	+3.00%	+0.98%	+15.12%	+48.39%	29.32B
IQVIA HOLDINGS INC.	+2.24%	-1.13%	-8.60%	-11.47%	27.68B
REVOLUTION MEDICINES, INC.	+0.33%	+0.71%	+154.45%	+359.46%	19.62B
ASCENDIS PHARMA A/S	-1.22%	-4.82%	+35.59%	+111.70%	14.18B
MEDPACE HOLDINGS, INC.	-0.13%	-2.96%	+38.80%	+157.88%	12.87B
EUROFINS SCIENTIFIC SE	+0.91%	-2.83%	+23.33%	+0.85%	12.39B
IONIS PHARMACEUTICALS, INC.	+0.56%	-3.48%	+112.90%	+107.58%	11.95B
Average	+0.71%	-3.23%	+37.29%	+70.13%	20.31B
Weighted average by Cap.	+0.71%	-3.72%	+27.49%	+67.00%